Upload
doananh
View
219
Download
3
Embed Size (px)
Citation preview
Indonesia 2016
Immunization system highlights
� There is a comprehensive multi-year plan (cMYP) for immunization covering 2015-2019.
� A standing national technical advisory group on immunization (NTAGI) fully functional.
� A national system to monitor adverse events following immunization (AEFI) exists.
� A national policy for health care waste management including waste from immunization activities exists.
� All 514 (100%) districts have updated micro-plans that include activities to raise immunization coverage.
� District coverage survey in 31 districts and 10 provinces was conducted in 2015.
� 83% spending on routine vaccine financed by the government.
� 76% spending on routine immunization programme financed by the central government.
� Out of 514 districts, 328 (64%) districts had > 80% coverage for DTP-Hib-HepB3, 217 (42%) districts had > 90% coverage for MCV1.
Source: WHO/UNICEF joint reporting form (JRF) 2015
Disclaimer: The boundaries and names shown and the designations used on all the maps do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries.
Table 1: Basic information1 2015Division/Province/State/Region 34
District 416
City 98
Village 79,411
Population density (per sq. km) 132
Population living in urban areas 52%
Population using improved drinking-water sources
85%
Population using improved sanitation 59%
Total expenditure on health as % of GDP 3.0%
Births attended by skilled health personnel 83%
Neonates protected at birth against NT 85%
Total population 255 461 686
Live births (LB) 4 893 435
Children <1 year 4 794 791
Children <5 years 24 065 506
Children <15 years 69 857 406
Pregnant women 5 382 779
Women of child bearing age (15-49 years)
51 981 127
Neonatal mortality rate 14.4 (per 1000 LB)
Infant mortality rate 24.5 (per 1000 LB)
Under-five mortality rate 29.3 (per 1000 LB)
Maternal mortality ratio 190 (per 100 000 LB)
1 SEAR annual EPI reporting form, 2015 and WHO, World Health Statistics 2015
Vaccine Age of administration
HepB 0 to 7 days of birth
BCG 1 month
OPV 1 month, 2 months, 3 months, 4 months
DTP-Hib-HepB 2 months, 3 months, 4 months, 18 months
Measles 9 months, 24 months
DT 6 -7 years
Td 7-8 years, 8-9 years
TT Females 15 to 39 years
Vitamin A 6 – 59 months
EPI history � EPI launched in 1977.
� HepB vaccine introduced in 1997.
� AD syringe introduced in 2002.
� MCV2 introduced in 2004.
� DTP-HepB vaccine introduced in 2004 (in phases)
� IPV introduced in one province in 2007.
� Hib Pentavalent (DTP-Hib-HepB) vaccine introduced in four provinces in 2013 and gradually expended to all provinces by 2014.
� Type 2 component of OPV withdrawn on 04 April 2016 by switching from tOPV to bOPV.
� IPV vaccine launched in national routine immunization programme from July 2016.
Table 2: Immunization schedule, 2015
Source: cMYP 2015-2019 and EPI/MOHSource: WHO/UNICEF joint reporting form (JRF) 2015
Figure 10: Immunity against measles: Immunity profile by age in 2015*
Figure 12: Confirmed (Lab and Epi linked) measles outbreak associated cases, by age, 2010-2015
Table 8: Suspected sporadic and Outbreak associated measles and rubella cases, 2010-2015
Table 9: Quality of field and laboratory surveillance for measles and rubella, 2012-2015
Table 10: Performance of Laboratory Surveillance, 2012-2015
Figure 14: Laboratory network
Figure 11: Immunity against measles: Immunity profile by age in 2016*
Figure 13: Unimmunized confirmed (Lab and Epi linked)measles outbreak associated cases, by age, 2010-2015
* Modeled using MSP tool ver 2 assuming the schedule and measles containing vaccine (MCV) coverage remain unchanged and Measles SIAs in 180 high risk districts in 2016.
* Modeled using MSP tool ver 2 based on coverage data up to 2015
Source: SEAR annual EPI reporting form
Source: Monthly VPD Reporting to WHO/SEARO * Laboratory confirmed & epidemiologically- linked
Source: SEAR Annual EPI Reporting Form, 2015 ND=No data
Source: SEAR Annual EPI Reporting Form, 2015 ND=No data
Source: SEAR annual EPI reporting form
Year
Routine/sporadic cases Outbreak associated cases
No. of suspected
case No. of death
No. of lab-confirmed
measles cases
No. of lab-confirmed
rubella cases
No. of suspected
outbreak
No. of Outbreak
Investigated No. of caseNo. of death
No. of measles
outbreak*
No. of confirmed
measles case*
No. of confirmed
rubella outbreak*
No. of confirmed
rubella cases*
2010 19 111 6 659 750 188 132 3 044 7 90 2 066 40 504
2011 23 282 0 1 175 1 808 356 286 4 993 14 251 3 747 60 586
2012 18 798 4 429 1 565 163 144 2 328 4 65 1 117 76 939
2013 11 521 1 689 707 128 96 1 677 1 71 803 24 310
2014 12 943 7 1471 713 173 119 2 104 21 114 1 285 7 69
2015 8 185 1 818 826 68 34 831 0 19 227 7 108
Year
No. o
f Sus
pect
ed M
easl
es
Case classification (number) Indicators
Measles Rubella
Disc
arde
d n
on-m
easl
es
non-
rube
lla c
ases
Annu
al in
cide
nce
of
confi
rmed
Mea
sles
cas
es
per m
illio
n to
tal p
opul
atio
n
Annu
al in
cide
nce
of
confi
rmed
Rub
ella
cas
es p
er
mill
ion
tota
l pop
ulat
ion
Prop
ortio
n of
all
susp
ecte
d m
easl
es a
nd ru
bella
cas
es
that
hav
e ha
d an
ade
quat
e in
vest
igat
ion
initi
ated
with
in
48 h
ours
of n
otifi
catio
n
Disc
arde
d no
n-m
easl
es
non-
rube
lla in
cide
nce
per
100
000
tota
l pop
ulat
ion
Prop
ortio
n of
sub
natio
nal
adm
inis
trativ
e un
its
repo
rting
at l
east
two
disc
arde
d no
n-m
easl
es n
on-
rube
lla c
ases
per
100
000
to
tal p
opul
atio
n
Prop
ortio
n of
sub
-nat
iona
l su
rvei
llanc
e un
its re
porti
ng
to th
e na
tiona
l lev
el o
n tim
e
Lab-
confi
rmed
Epi-L
inke
d
Clin
ical
ly-c
onfir
med
Lab-
confi
rmed
Epi-L
inke
d
Target - - 80% 2 80% 80%
2012 18 798 429 ND ND 1 565 ND 1 561 1.75 6.18 ND 0.61 ND 64.23
2013 11 521 747 ND ND 742 ND 1 376 3.01 2.93 ND 0.54 ND 60.22
2014 12 943 2 241 ND ND 906 ND 2 606 8.85 3.58 ND 1.03 ND 22.06
2015 8 185 818 ND ND 826 ND 1 434 3.23 3.26 ND 0.57 ND 37.76
Year
% Serum specimen collected from
suspected measles cases
Total Serum Specimen
received in Laboratory
% serum specimens
tested
Specimen Positive for
Measles IgM
Specimen Positive for Rubella IgM
% Results within 4 of
receipt
% Outbreak tested
for viral detection
Genotypes detected
No. % No. % Measles Rubella
2012 25 4 657 89 403 10% 921 25% 68 ND ND ND
2013 45 5 169 100 996 20% 1 042 25% 97 ND ND ND
2014 65 8 448 99 5 194 62% 1 140 36% 60 2 ND ND
2015 142 11 608 99 2 511 22% 4 239 47% 40 ND ND ND
For contact or feedback:
Expanded Program on Immunization
Ministry of Health, Jakarta, Indonesia
Tel : +62 21 4257044, Fax: +62 21 4257044
Email: [email protected] or [email protected]
www.depkes.go.id
Immunization and Vaccine Development (IVD)WHO-SEARO, IP Estate, MG Marg, New Delhi 110002, India
Tel: +91 11 23370804, Fax: +91 11 23370251
Email: [email protected], www.searo.who.int/entity/immunization
0%10%20%30%40%50%60%70%80%90%
100%
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19
Perce
nt of
popu
lation
Age (in years)Susceptible Immune due to past infectionProtected by SIAs Protected by routine vaccination with 2nd doseProtected by routine vaccination with 1st dose Protected by maternal antibodies
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19
Perce
nt of
popu
lation
Age (in years)Protected by maternal antibodies Protected by routine vaccination with 1st doseProtected by routine vaccination with 2nd dose Protected by SIAsImmune due to past infection Susceptible
0100200300400500600700800900
2010 2011 2012 2013 2014 2015
<1 year 1-4 years 5-9 years 10-14 years 15+ years
n=1627 n=2617 n=1119 n=365 n=1553 n=227
050
100150200250300350400450500
2010 2011 2012 2013 2014 2015
<1 year 1-4 years 5-9 years 10-14 years 15+ years
n=1107(68%)
n=1468(56%)
n=775(69%)
n=280(77%)
ND ND
Polio, measles & rubella laboratoriesNational Institute of Health Research and Development (NIHRD), JakartaBiofarma, BandungPublic Health Laboratory, Surabaya
Japanese encephalitis laboratory NIHRD, JakartaPublic Health Laboratory, Denpasar
Measles & rubella laboratoryPublic Health Laboratory, YogyakartaPublic Health Laboratory, PalembangPublic Health Laboratory, MakassarPublic Health Laboratory, Jakarta
E P I F a c t S h E E t
World Health Organization• SEARO/FGL/IVD • 31 August 2016 Immunization andVaccine Development
South-East Asia Region
World Health Organization• SEARO/FGL/IVD • 31 August 2016 Immunization andVaccine Development
South-East Asia Region
E P I F a c t S h E E t
World Health Organization• SEARO/FGL/IVD • 31 August 2016 Immunization andVaccine Development
South-East Asia Region
Figure 1: National immunization coverage, 1980-2015
Figure 3: DTP-Hib-HepB3 coverage by province, 2015
Figure 5: Non-polio AFP rate by province, 2015
Figure 7: MCV1 & MCV2 coverage1 and measles cases2, 1980–2015
Figure 9: Sporadic and outbreak associated measles cases* by month and MR SIA coverage, 2010-2015
Table 3: OPV supplementary immunization activities (SIA)
Figure 2: DTP3 coverage1, diphtheria and pertussis cases2, 1980–2015
Figure 4: TT2+ coverage1 and NT cases2, 1980–2015
Figure 6: Adequate stool specimen collection percentage by province, 2015
Figure 8: MCV1 coverage by province, 2015
1 WHO and UNICEF estimates of national immunization coverage, July 2016 revision2 WHO vaccine-preventable diseases: monitoring system 2016
Source: WHO and UNICEF estimates of national immunization coverage, July 2016 revision
Source: SEAR annual EPI reporting form, 2015 (administrative data)
Source: SEAR annual EPI reporting form, 2015 (administrative data)
* During measles campaign ** Except Yogyakarta Source: WHO/UNICEF JRF
1 Country official estimates, 1980-20152 WHO vaccine-preventable diseases: monitoring system 2016
• Indonesia achieved the maternal neonatal tetanus (MNT) elimination status in May 2016.
Indicator 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015
AFP cases 1526 1557 1684 1724 1641 1720 1951 1963 1765 1428
Wild poliovirus confirmed cases 2 0 0 0 0 0 0 0 0 0
Compatible cases 15 4 1 0 0 0 0 0 0 0
AFP rate 2.48 2.52 2.75 2.83 2.62 2.75 2.76 2.74 2.43 2.04
Non-polio AFP rate1 2.45 2.52 2.75 2.83 2.62 2.75 2.76 2.74 2.43 2.04
Adequate stool specimen collection percentage2 83% 85% 84% 86% 85% 91% 92% 88% 89% 92%
Total stool samples collected 2978 3020 3328 3343 3184 3386 3828 3826 3424 2801
% NPEV isolation 12 12 9 8 9 9 9 9 7 7
% Timeliness of primary result reported3 100 100 99 99 100 99 99 99 98 99
Table 4: AFP surveillance performance indicators, 2006–2015
• The last polio case due to wild polio virus (WPV) was reported from Tenggara district, Aceh on 20 February 2006.
Year Activity Target population (<5 years)
Date of 1st round Date of 2nd round 1st round coverage (%)
2nd round coverage (%)
2002 NID 20 031 168 Sep-2002 Oct-2002 107 109
2005 SNID 6 287 418 May-2005 Jun-2005 104 93
2005 NID 23 426 156 Aug-2005 Sep-2005 95 98
2005 NID 23 620 427 Nov-2005 – 98 –
2006 SNID 3 050 873 Jan-2006 – 98 –
2006 NID 23 620 427 Feb-2006 Apr-2006 99 100
2006 SNID 4 523 187 Jun-2006 Aug-2006 96 98
2006 SNID 6 045 438 Sep-2006 – 92 –
2007 SNID 12 517 699 Feb-2007 Aug-2007 90 92
2009 SNID* 2 052 067 Oct-2009 – 97 –
2010 SNID* 4 322 178 Oct-2010 – 92 –
2011 SNID* 13 958 095 Oct-2011 – 98 –
2016 NID** 23 721 004 Mar-2016 – 97 –
1 Number of discarded AFP cases per 100,000 children under 15 years of age. 2 Percent with 2 specimens, 24 hours apart and within 14 days of paralysis onset.3 2005 to 2007 result reported within 28 days and 2008 onwards result reported within 14 days of sample received at laboratory.
Year Polio Diphtheria Pertussis Neonatal Tetanus (% of all Tetanus)
Measles Rubella Mumps Japanese Encephalitis
Congenital Rubella Syndrome
2006 2 162 3356 118 (37%) 20 422 105 ND ND ND
2007 0 183 ND 141 (100%) 19 456 168 ND ND ND
2008 0 219 ND 183 (100%) 15 369 340 ND ND ND
2009 0 189 973 158 (68%) 20 818 2090 ND ND ND
2010 0 432 ND 147 (100%) 18 869 1323 ND ND ND
2011 0 806 1941 114 (54%) 21 893 1959 ND ND ND
2012 0 1192 ND 106 15 489 1020 ND ND ND
2013 0 775 2976 78 (35%) 8 419 2355 ND ND ND
2014 0 430 2082 75 (7%) 12 943 3542 ND 72 ND
2015 0 252 1004 69 (ND) 818 826 ND 39 44
Year Activity Age Target Coverage (%)2000 Sub-national 6-12 Y 6 665 950 952003 Sub-national 6-12 Y 1 030 445 952004 Sub-national 6-12 Y 2 180 918 942005 Sub-national 6 M-15 Y 5 515 324 942006 Sub-national 6 M-5 Y 3 978 096 932006 Sub-national 6-12 Y 3 161 323 962007 Sub-national 6 M-12 Y 2 692 912 1062007 Sub-national 6 Y-12 Y 2 569 350 1022007 Sub-national 6-59 M 14 916 592 932008 Sub-national 1-3 Y 11 203 782009 Sub-national 9-59 M 1 763 122 97
2010 Sub-national 9-59 M 3 619 024 92
2011 Sub-national 9-59 M 11 843 093 98
Year Number of districts %
2010 197 40
2011 198 40
2012 269 54
2013 226 45
2014 207 41
2015 137 27
Table 5: Reported cases of vaccine preventable disease, 2006-2015
Table 6: MCV supplementary immunization activities Table 7: Districts with more than 95% MCV1 coverage
Source: WHO/UNICEF JRF ND=No data
1 WHO and UNICEF estimates of national immunization coverage, July 2016 revision2 WHO vaccine-preventable diseases: monitoring system 2016
Source: WHO/UNICEF JRFs
Source: WHO/UNICEF JRF
0
20
40
60
80
100
0
2000
4000
6000
8000
10000
12000
1980 1985 1990 1995 2000 2005 2010 2011 2012 2013 2014 2015
% C
over
age
No. o
f cas
es
Year
Diphtheria Cases Pertussis Cases DTP3 Coverage
32999 30014
*Includes laboratory confirmed and epidemiologically linked casesSource: SEAR Monthly VPD reports.
1980 1985 1990 1995 2000 2005 2010 2011 2012 2013 2014 2015BCG 61 65 74 77 81 86 88 98 88 86 81 77DTP3 27 60 69 75 72 81 81 83 85 81 81OPV3 13 60 71 72 79 82 81 84 86 82 82MCV1 26 58 63 76 77 78 80 82 81 77 69
0
20
40
60
80
100
% C
over
age
<70% 70%-79% >90%80%-89%0
20
40
60
80
100
0200400600800
1000120014001600
1980 1985 1990 1995 2000 2005 2010 2011 2012 2013 2014 2015
% C
over
age
No. o
f cas
es
YearNT cases TT2+ Coverage <1 1–1.99 >2 No non -polio AFP case < 60% 60% – 79% > 80% No AFP
92105
0
20
40
60
80
100
05000
100001500020000250003000035000400004500050000
1980 1985 1990 1995 2000 2005 2010 2011 2012 2013 2014 2015
% C
over
age
No. o
f cas
es
YearMeasles Cases MCV1 Coverage MCV2 Coverage
<70% 70% – 79% 80% – 89% >90%
Sporadic measles Outbreak associated measles
0
100
200
300
400
M, SIA (92%) M, SIA (98%)
500
600
Jan-
10
Mar-1
0
May-1
0
Jul-1
0
Sep-
10
Nov-1
0
Jan-
11
Mar-1
1
May-1
1
Jul-1
1
Sep-
11
Nov-1
1
Jan-
12
Mar-1
2
May-1
2
Jul-1
2
Sep-
12
Nov-1
2
Jan-
13
Mar-1
3
May-1
3
Jul-1
3
Sep-
13
Nov-1
3
Jan-
14
Mar-1
4
May-1
4
Jul-1
4
Sep-
14
Nov-1
4
Jan-
15
Mar-1
5
May-1
5
Jul-1
5
Sep-
15
Nov-1
5
No. o
f cas
es
E P I F a c t S h E E t
World Health Organization• SEARO/FGL/IVD • 31 August 2016 Immunization andVaccine Development
South-East Asia Region
Figure 1: National immunization coverage, 1980-2015
Figure 3: DTP-Hib-HepB3 coverage by province, 2015
Figure 5: Non-polio AFP rate by province, 2015
Figure 7: MCV1 & MCV2 coverage1 and measles cases2, 1980–2015
Figure 9: Sporadic and outbreak associated measles cases* by month and MR SIA coverage, 2010-2015
Table 3: OPV supplementary immunization activities (SIA)
Figure 2: DTP3 coverage1, diphtheria and pertussis cases2, 1980–2015
Figure 4: TT2+ coverage1 and NT cases2, 1980–2015
Figure 6: Adequate stool specimen collection percentage by province, 2015
Figure 8: MCV1 coverage by province, 2015
1 WHO and UNICEF estimates of national immunization coverage, July 2016 revision2 WHO vaccine-preventable diseases: monitoring system 2016
Source: WHO and UNICEF estimates of national immunization coverage, July 2016 revision
Source: SEAR annual EPI reporting form, 2015 (administrative data)
Source: SEAR annual EPI reporting form, 2015 (administrative data)
* During measles campaign ** Except Yogyakarta Source: WHO/UNICEF JRF
1 Country official estimates, 1980-20152 WHO vaccine-preventable diseases: monitoring system 2016
• Indonesia achieved the maternal neonatal tetanus (MNT) elimination status in May 2016.
Indicator 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015
AFP cases 1526 1557 1684 1724 1641 1720 1951 1963 1765 1428
Wild poliovirus confirmed cases 2 0 0 0 0 0 0 0 0 0
Compatible cases 15 4 1 0 0 0 0 0 0 0
AFP rate 2.48 2.52 2.75 2.83 2.62 2.75 2.76 2.74 2.43 2.04
Non-polio AFP rate1 2.45 2.52 2.75 2.83 2.62 2.75 2.76 2.74 2.43 2.04
Adequate stool specimen collection percentage2 83% 85% 84% 86% 85% 91% 92% 88% 89% 92%
Total stool samples collected 2978 3020 3328 3343 3184 3386 3828 3826 3424 2801
% NPEV isolation 12 12 9 8 9 9 9 9 7 7
% Timeliness of primary result reported3 100 100 99 99 100 99 99 99 98 99
Table 4: AFP surveillance performance indicators, 2006–2015
• The last polio case due to wild polio virus (WPV) was reported from Tenggara district, Aceh on 20 February 2006.
Year Activity Target population (<5 years)
Date of 1st round Date of 2nd round 1st round coverage (%)
2nd round coverage (%)
2002 NID 20 031 168 Sep-2002 Oct-2002 107 109
2005 SNID 6 287 418 May-2005 Jun-2005 104 93
2005 NID 23 426 156 Aug-2005 Sep-2005 95 98
2005 NID 23 620 427 Nov-2005 – 98 –
2006 SNID 3 050 873 Jan-2006 – 98 –
2006 NID 23 620 427 Feb-2006 Apr-2006 99 100
2006 SNID 4 523 187 Jun-2006 Aug-2006 96 98
2006 SNID 6 045 438 Sep-2006 – 92 –
2007 SNID 12 517 699 Feb-2007 Aug-2007 90 92
2009 SNID* 2 052 067 Oct-2009 – 97 –
2010 SNID* 4 322 178 Oct-2010 – 92 –
2011 SNID* 13 958 095 Oct-2011 – 98 –
2016 NID** 23 721 004 Mar-2016 – 97 –
1 Number of discarded AFP cases per 100,000 children under 15 years of age. 2 Percent with 2 specimens, 24 hours apart and within 14 days of paralysis onset.3 2005 to 2007 result reported within 28 days and 2008 onwards result reported within 14 days of sample received at laboratory.
Year Polio Diphtheria Pertussis Neonatal Tetanus (% of all Tetanus)
Measles Rubella Mumps Japanese Encephalitis
Congenital Rubella Syndrome
2006 2 162 3356 118 (37%) 20 422 105 ND ND ND
2007 0 183 ND 141 (100%) 19 456 168 ND ND ND
2008 0 219 ND 183 (100%) 15 369 340 ND ND ND
2009 0 189 973 158 (68%) 20 818 2090 ND ND ND
2010 0 432 ND 147 (100%) 18 869 1323 ND ND ND
2011 0 806 1941 114 (54%) 21 893 1959 ND ND ND
2012 0 1192 ND 106 15 489 1020 ND ND ND
2013 0 775 2976 78 (35%) 8 419 2355 ND ND ND
2014 0 430 2082 75 (7%) 12 943 3542 ND 72 ND
2015 0 252 1004 69 (ND) 818 826 ND 39 44
Year Activity Age Target Coverage (%)2000 Sub-national 6-12 Y 6 665 950 952003 Sub-national 6-12 Y 1 030 445 952004 Sub-national 6-12 Y 2 180 918 942005 Sub-national 6 M-15 Y 5 515 324 942006 Sub-national 6 M-5 Y 3 978 096 932006 Sub-national 6-12 Y 3 161 323 962007 Sub-national 6 M-12 Y 2 692 912 1062007 Sub-national 6 Y-12 Y 2 569 350 1022007 Sub-national 6-59 M 14 916 592 932008 Sub-national 1-3 Y 11 203 782009 Sub-national 9-59 M 1 763 122 97
2010 Sub-national 9-59 M 3 619 024 92
2011 Sub-national 9-59 M 11 843 093 98
Year Number of districts %
2010 197 40
2011 198 40
2012 269 54
2013 226 45
2014 207 41
2015 137 27
Table 5: Reported cases of vaccine preventable disease, 2006-2015
Table 6: MCV supplementary immunization activities Table 7: Districts with more than 95% MCV1 coverage
Source: WHO/UNICEF JRF ND=No data
1 WHO and UNICEF estimates of national immunization coverage, July 2016 revision2 WHO vaccine-preventable diseases: monitoring system 2016
Source: WHO/UNICEF JRFs
Source: WHO/UNICEF JRF
0
20
40
60
80
100
0
2000
4000
6000
8000
10000
12000
1980 1985 1990 1995 2000 2005 2010 2011 2012 2013 2014 2015
% C
over
age
No. o
f cas
es
Year
Diphtheria Cases Pertussis Cases DTP3 Coverage
32999 30014
*Includes laboratory confirmed and epidemiologically linked casesSource: SEAR Monthly VPD reports.
1980 1985 1990 1995 2000 2005 2010 2011 2012 2013 2014 2015BCG 61 65 74 77 81 86 88 98 88 86 81 77DTP3 27 60 69 75 72 81 81 83 85 81 81OPV3 13 60 71 72 79 82 81 84 86 82 82MCV1 26 58 63 76 77 78 80 82 81 77 69
0
20
40
60
80
100
% C
over
age
<70% 70%-79% >90%80%-89%0
20
40
60
80
100
0200400600800
1000120014001600
1980 1985 1990 1995 2000 2005 2010 2011 2012 2013 2014 2015
% C
over
age
No. o
f cas
es
YearNT cases TT2+ Coverage <1 1–1.99 >2 No non -polio AFP case < 60% 60% – 79% > 80% No AFP
92105
0
20
40
60
80
100
05000
100001500020000250003000035000400004500050000
1980 1985 1990 1995 2000 2005 2010 2011 2012 2013 2014 2015
% C
over
age
No. o
f cas
es
YearMeasles Cases MCV1 Coverage MCV2 Coverage
<70% 70% – 79% 80% – 89% >90%
Sporadic measles Outbreak associated measles
0
100
200
300
400
M, SIA (92%) M, SIA (98%)
500
600
Jan-
10
Mar-1
0
May-1
0
Jul-1
0
Sep-
10
Nov-1
0
Jan-
11
Mar-1
1
May-1
1
Jul-1
1
Sep-
11
Nov-1
1
Jan-
12
Mar-1
2
May-1
2
Jul-1
2
Sep-
12
Nov-1
2
Jan-
13
Mar-1
3
May-1
3
Jul-1
3
Sep-
13
Nov-1
3
Jan-
14
Mar-1
4
May-1
4
Jul-1
4
Sep-
14
Nov-1
4
Jan-
15
Mar-1
5
May-1
5
Jul-1
5
Sep-
15
Nov-1
5
No. o
f cas
es
E P I F a c t S h E E t
World Health Organization• SEARO/FGL/IVD • 31 August 2016 Immunization andVaccine Development
South-East Asia Region
Figure 1: National immunization coverage, 1980-2015
Figure 3: DTP-Hib-HepB3 coverage by province, 2015
Figure 5: Non-polio AFP rate by province, 2015
Figure 7: MCV1 & MCV2 coverage1 and measles cases2, 1980–2015
Figure 9: Sporadic and outbreak associated measles cases* by month and MR SIA coverage, 2010-2015
Table 3: OPV supplementary immunization activities (SIA)
Figure 2: DTP3 coverage1, diphtheria and pertussis cases2, 1980–2015
Figure 4: TT2+ coverage1 and NT cases2, 1980–2015
Figure 6: Adequate stool specimen collection percentage by province, 2015
Figure 8: MCV1 coverage by province, 2015
1 WHO and UNICEF estimates of national immunization coverage, July 2016 revision2 WHO vaccine-preventable diseases: monitoring system 2016
Source: WHO and UNICEF estimates of national immunization coverage, July 2016 revision
Source: SEAR annual EPI reporting form, 2015 (administrative data)
Source: SEAR annual EPI reporting form, 2015 (administrative data)
* During measles campaign ** Except Yogyakarta Source: WHO/UNICEF JRF
1 Country official estimates, 1980-20152 WHO vaccine-preventable diseases: monitoring system 2016
• Indonesia achieved the maternal neonatal tetanus (MNT) elimination status in May 2016.
Indicator 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015
AFP cases 1526 1557 1684 1724 1641 1720 1951 1963 1765 1428
Wild poliovirus confirmed cases 2 0 0 0 0 0 0 0 0 0
Compatible cases 15 4 1 0 0 0 0 0 0 0
AFP rate 2.48 2.52 2.75 2.83 2.62 2.75 2.76 2.74 2.43 2.04
Non-polio AFP rate1 2.45 2.52 2.75 2.83 2.62 2.75 2.76 2.74 2.43 2.04
Adequate stool specimen collection percentage2 83% 85% 84% 86% 85% 91% 92% 88% 89% 92%
Total stool samples collected 2978 3020 3328 3343 3184 3386 3828 3826 3424 2801
% NPEV isolation 12 12 9 8 9 9 9 9 7 7
% Timeliness of primary result reported3 100 100 99 99 100 99 99 99 98 99
Table 4: AFP surveillance performance indicators, 2006–2015
• The last polio case due to wild polio virus (WPV) was reported from Tenggara district, Aceh on 20 February 2006.
Year Activity Target population (<5 years)
Date of 1st round Date of 2nd round 1st round coverage (%)
2nd round coverage (%)
2002 NID 20 031 168 Sep-2002 Oct-2002 107 109
2005 SNID 6 287 418 May-2005 Jun-2005 104 93
2005 NID 23 426 156 Aug-2005 Sep-2005 95 98
2005 NID 23 620 427 Nov-2005 – 98 –
2006 SNID 3 050 873 Jan-2006 – 98 –
2006 NID 23 620 427 Feb-2006 Apr-2006 99 100
2006 SNID 4 523 187 Jun-2006 Aug-2006 96 98
2006 SNID 6 045 438 Sep-2006 – 92 –
2007 SNID 12 517 699 Feb-2007 Aug-2007 90 92
2009 SNID* 2 052 067 Oct-2009 – 97 –
2010 SNID* 4 322 178 Oct-2010 – 92 –
2011 SNID* 13 958 095 Oct-2011 – 98 –
2016 NID** 23 721 004 Mar-2016 – 97 –
1 Number of discarded AFP cases per 100,000 children under 15 years of age. 2 Percent with 2 specimens, 24 hours apart and within 14 days of paralysis onset.3 2005 to 2007 result reported within 28 days and 2008 onwards result reported within 14 days of sample received at laboratory.
Year Polio Diphtheria Pertussis Neonatal Tetanus (% of all Tetanus)
Measles Rubella Mumps Japanese Encephalitis
Congenital Rubella Syndrome
2006 2 162 3356 118 (37%) 20 422 105 ND ND ND
2007 0 183 ND 141 (100%) 19 456 168 ND ND ND
2008 0 219 ND 183 (100%) 15 369 340 ND ND ND
2009 0 189 973 158 (68%) 20 818 2090 ND ND ND
2010 0 432 ND 147 (100%) 18 869 1323 ND ND ND
2011 0 806 1941 114 (54%) 21 893 1959 ND ND ND
2012 0 1192 ND 106 15 489 1020 ND ND ND
2013 0 775 2976 78 (35%) 8 419 2355 ND ND ND
2014 0 430 2082 75 (7%) 12 943 3542 ND 72 ND
2015 0 252 1004 69 (ND) 818 826 ND 39 44
Year Activity Age Target Coverage (%)2000 Sub-national 6-12 Y 6 665 950 952003 Sub-national 6-12 Y 1 030 445 952004 Sub-national 6-12 Y 2 180 918 942005 Sub-national 6 M-15 Y 5 515 324 942006 Sub-national 6 M-5 Y 3 978 096 932006 Sub-national 6-12 Y 3 161 323 962007 Sub-national 6 M-12 Y 2 692 912 1062007 Sub-national 6 Y-12 Y 2 569 350 1022007 Sub-national 6-59 M 14 916 592 932008 Sub-national 1-3 Y 11 203 782009 Sub-national 9-59 M 1 763 122 97
2010 Sub-national 9-59 M 3 619 024 92
2011 Sub-national 9-59 M 11 843 093 98
Year Number of districts %
2010 197 40
2011 198 40
2012 269 54
2013 226 45
2014 207 41
2015 137 27
Table 5: Reported cases of vaccine preventable disease, 2006-2015
Table 6: MCV supplementary immunization activities Table 7: Districts with more than 95% MCV1 coverage
Source: WHO/UNICEF JRF ND=No data
1 WHO and UNICEF estimates of national immunization coverage, July 2016 revision2 WHO vaccine-preventable diseases: monitoring system 2016
Source: WHO/UNICEF JRFs
Source: WHO/UNICEF JRF
0
20
40
60
80
100
0
2000
4000
6000
8000
10000
12000
1980 1985 1990 1995 2000 2005 2010 2011 2012 2013 2014 2015
% C
over
age
No. o
f cas
es
Year
Diphtheria Cases Pertussis Cases DTP3 Coverage
32999 30014
*Includes laboratory confirmed and epidemiologically linked casesSource: SEAR Monthly VPD reports.
1980 1985 1990 1995 2000 2005 2010 2011 2012 2013 2014 2015BCG 61 65 74 77 81 86 88 98 88 86 81 77DTP3 27 60 69 75 72 81 81 83 85 81 81OPV3 13 60 71 72 79 82 81 84 86 82 82MCV1 26 58 63 76 77 78 80 82 81 77 69
0
20
40
60
80
100
% C
over
age
<70% 70%-79% >90%80%-89%0
20
40
60
80
100
0200400600800
1000120014001600
1980 1985 1990 1995 2000 2005 2010 2011 2012 2013 2014 2015
% C
over
age
No. o
f cas
es
YearNT cases TT2+ Coverage <1 1–1.99 >2 No non -polio AFP case < 60% 60% – 79% > 80% No AFP
92105
0
20
40
60
80
100
05000
100001500020000250003000035000400004500050000
1980 1985 1990 1995 2000 2005 2010 2011 2012 2013 2014 2015
% C
over
age
No. o
f cas
es
YearMeasles Cases MCV1 Coverage MCV2 Coverage
<70% 70% – 79% 80% – 89% >90%
Sporadic measles Outbreak associated measles
0
100
200
300
400
M, SIA (92%) M, SIA (98%)
500
600
Jan-
10
Mar-1
0
May-1
0
Jul-1
0
Sep-
10
Nov-1
0
Jan-
11
Mar-1
1
May-1
1
Jul-1
1
Sep-
11
Nov-1
1
Jan-
12
Mar-1
2
May-1
2
Jul-1
2
Sep-
12
Nov-1
2
Jan-
13
Mar-1
3
May-1
3
Jul-1
3
Sep-
13
Nov-1
3
Jan-
14
Mar-1
4
May-1
4
Jul-1
4
Sep-
14
Nov-1
4
Jan-
15
Mar-1
5
May-1
5
Jul-1
5
Sep-
15
Nov-1
5
No. o
f cas
es
Indonesia 2016
Immunization system highlights
� There is a comprehensive multi-year plan (cMYP) for immunization covering 2015-2019.
� A standing national technical advisory group on immunization (NTAGI) fully functional.
� A national system to monitor adverse events following immunization (AEFI) exists.
� A national policy for health care waste management including waste from immunization activities exists.
� All 514 (100%) districts have updated micro-plans that include activities to raise immunization coverage.
� District coverage survey in 31 districts and 10 provinces was conducted in 2015.
� 83% spending on routine vaccine financed by the government.
� 76% spending on routine immunization programme financed by the central government.
� Out of 514 districts, 328 (64%) districts had > 80% coverage for DTP-Hib-HepB3, 217 (42%) districts had > 90% coverage for MCV1.
Source: WHO/UNICEF joint reporting form (JRF) 2015
Disclaimer: The boundaries and names shown and the designations used on all the maps do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries.
Table 1: Basic information1 2015Division/Province/State/Region 34
District 416
City 98
Village 79,411
Population density (per sq. km) 132
Population living in urban areas 52%
Population using improved drinking-water sources
85%
Population using improved sanitation 59%
Total expenditure on health as % of GDP 3.0%
Births attended by skilled health personnel 83%
Neonates protected at birth against NT 85%
Total population 255 461 686
Live births (LB) 4 893 435
Children <1 year 4 794 791
Children <5 years 24 065 506
Children <15 years 69 857 406
Pregnant women 5 382 779
Women of child bearing age (15-49 years)
51 981 127
Neonatal mortality rate 14.4 (per 1000 LB)
Infant mortality rate 24.5 (per 1000 LB)
Under-five mortality rate 29.3 (per 1000 LB)
Maternal mortality ratio 190 (per 100 000 LB)
1 SEAR annual EPI reporting form, 2015 and WHO, World Health Statistics 2015
Vaccine Age of administration
HepB 0 to 7 days of birth
BCG 1 month
OPV 1 month, 2 months, 3 months, 4 months
DTP-Hib-HepB 2 months, 3 months, 4 months, 18 months
Measles 9 months, 24 months
DT 6 -7 years
Td 7-8 years, 8-9 years
TT Females 15 to 39 years
Vitamin A 6 – 59 months
EPI history � EPI launched in 1977.
� HepB vaccine introduced in 1997.
� AD syringe introduced in 2002.
� MCV2 introduced in 2004.
� DTP-HepB vaccine introduced in 2004 (in phases)
� IPV introduced in one province in 2007.
� Hib Pentavalent (DTP-Hib-HepB) vaccine introduced in four provinces in 2013 and gradually expended to all provinces by 2014.
� Type 2 component of OPV withdrawn on 04 April 2016 by switching from tOPV to bOPV.
� IPV vaccine launched in national routine immunization programme from July 2016.
Table 2: Immunization schedule, 2015
Source: cMYP 2015-2019 and EPI/MOHSource: WHO/UNICEF joint reporting form (JRF) 2015
Figure 10: Immunity against measles: Immunity profile by age in 2015*
Figure 12: Confirmed (Lab and Epi linked) measles outbreak associated cases, by age, 2010-2015
Table 8: Suspected sporadic and Outbreak associated measles and rubella cases, 2010-2015
Table 9: Quality of field and laboratory surveillance for measles and rubella, 2012-2015
Table 10: Performance of Laboratory Surveillance, 2012-2015
Figure 14: Laboratory network
Figure 11: Immunity against measles: Immunity profile by age in 2016*
Figure 13: Unimmunized confirmed (Lab and Epi linked)measles outbreak associated cases, by age, 2010-2015
* Modeled using MSP tool ver 2 assuming the schedule and measles containing vaccine (MCV) coverage remain unchanged and Measles SIAs in 180 high risk districts in 2016.
* Modeled using MSP tool ver 2 based on coverage data up to 2015
Source: SEAR annual EPI reporting form
Source: Monthly VPD Reporting to WHO/SEARO * Laboratory confirmed & epidemiologically- linked
Source: SEAR Annual EPI Reporting Form, 2015 ND=No data
Source: SEAR Annual EPI Reporting Form, 2015 ND=No data
Source: SEAR annual EPI reporting form
Year
Routine/sporadic cases Outbreak associated cases
No. of suspected
case No. of death
No. of lab-confirmed
measles cases
No. of lab-confirmed
rubella cases
No. of suspected
outbreak
No. of Outbreak
Investigated No. of caseNo. of death
No. of measles
outbreak*
No. of confirmed
measles case*
No. of confirmed
rubella outbreak*
No. of confirmed
rubella cases*
2010 19 111 6 659 750 188 132 3 044 7 90 2 066 40 504
2011 23 282 0 1 175 1 808 356 286 4 993 14 251 3 747 60 586
2012 18 798 4 429 1 565 163 144 2 328 4 65 1 117 76 939
2013 11 521 1 689 707 128 96 1 677 1 71 803 24 310
2014 12 943 7 1471 713 173 119 2 104 21 114 1 285 7 69
2015 8 185 1 818 826 68 34 831 0 19 227 7 108
Year
No. o
f Sus
pect
ed M
easl
es
Case classification (number) Indicators
Measles Rubella
Disc
arde
d n
on-m
easl
es
non-
rube
lla c
ases
Annu
al in
cide
nce
of
confi
rmed
Mea
sles
cas
es
per m
illio
n to
tal p
opul
atio
n
Annu
al in
cide
nce
of
confi
rmed
Rub
ella
cas
es p
er
mill
ion
tota
l pop
ulat
ion
Prop
ortio
n of
all
susp
ecte
d m
easl
es a
nd ru
bella
cas
es
that
hav
e ha
d an
ade
quat
e in
vest
igat
ion
initi
ated
with
in
48 h
ours
of n
otifi
catio
n
Disc
arde
d no
n-m
easl
es
non-
rube
lla in
cide
nce
per
100
000
tota
l pop
ulat
ion
Prop
ortio
n of
sub
natio
nal
adm
inis
trativ
e un
its
repo
rting
at l
east
two
disc
arde
d no
n-m
easl
es n
on-
rube
lla c
ases
per
100
000
to
tal p
opul
atio
n
Prop
ortio
n of
sub
-nat
iona
l su
rvei
llanc
e un
its re
porti
ng
to th
e na
tiona
l lev
el o
n tim
e
Lab-
confi
rmed
Epi-L
inke
d
Clin
ical
ly-c
onfir
med
Lab-
confi
rmed
Epi-L
inke
d
Target - - 80% 2 80% 80%
2012 18 798 429 ND ND 1 565 ND 1 561 1.75 6.18 ND 0.61 ND 64.23
2013 11 521 747 ND ND 742 ND 1 376 3.01 2.93 ND 0.54 ND 60.22
2014 12 943 2 241 ND ND 906 ND 2 606 8.85 3.58 ND 1.03 ND 22.06
2015 8 185 818 ND ND 826 ND 1 434 3.23 3.26 ND 0.57 ND 37.76
Year
% Serum specimen collected from
suspected measles cases
Total Serum Specimen
received in Laboratory
% serum specimens
tested
Specimen Positive for
Measles IgM
Specimen Positive for Rubella IgM
% Results within 4 of
receipt
% Outbreak tested
for viral detection
Genotypes detected
No. % No. % Measles Rubella
2012 25 4 657 89 403 10% 921 25% 68 ND ND ND
2013 45 5 169 100 996 20% 1 042 25% 97 ND ND ND
2014 65 8 448 99 5 194 62% 1 140 36% 60 2 ND ND
2015 142 11 608 99 2 511 22% 4 239 47% 40 ND ND ND
For contact or feedback:
Expanded Program on Immunization
Ministry of Health, Jakarta, Indonesia
Tel : +62 21 4257044, Fax: +62 21 4257044
Email: [email protected] or [email protected]
www.depkes.go.id
Immunization and Vaccine Development (IVD)WHO-SEARO, IP Estate, MG Marg, New Delhi 110002, India
Tel: +91 11 23370804, Fax: +91 11 23370251
Email: [email protected], www.searo.who.int/entity/immunization
0%10%20%30%40%50%60%70%80%90%
100%
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19
Perce
nt of
popu
lation
Age (in years)Susceptible Immune due to past infectionProtected by SIAs Protected by routine vaccination with 2nd doseProtected by routine vaccination with 1st dose Protected by maternal antibodies
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19
Perce
nt of
popu
lation
Age (in years)Protected by maternal antibodies Protected by routine vaccination with 1st doseProtected by routine vaccination with 2nd dose Protected by SIAsImmune due to past infection Susceptible
0100200300400500600700800900
2010 2011 2012 2013 2014 2015
<1 year 1-4 years 5-9 years 10-14 years 15+ years
n=1627 n=2617 n=1119 n=365 n=1553 n=227
050
100150200250300350400450500
2010 2011 2012 2013 2014 2015
<1 year 1-4 years 5-9 years 10-14 years 15+ years
n=1107(68%)
n=1468(56%)
n=775(69%)
n=280(77%)
ND ND
Polio, measles & rubella laboratoriesNational Institute of Health Research and Development (NIHRD), JakartaBiofarma, BandungPublic Health Laboratory, Surabaya
Japanese encephalitis laboratory NIHRD, JakartaPublic Health Laboratory, Denpasar
Measles & rubella laboratoryPublic Health Laboratory, YogyakartaPublic Health Laboratory, PalembangPublic Health Laboratory, MakassarPublic Health Laboratory, Jakarta
E P I F a c t S h E E t
World Health Organization• SEARO/FGL/IVD • 31 August 2016 Immunization andVaccine Development
South-East Asia Region
World Health Organization• SEARO/FGL/IVD • 31 August 2016 Immunization andVaccine Development
South-East Asia Region
Indonesia 2016
Immunization system highlights
� There is a comprehensive multi-year plan (cMYP) for immunization covering 2015-2019.
� A standing national technical advisory group on immunization (NTAGI) fully functional.
� A national system to monitor adverse events following immunization (AEFI) exists.
� A national policy for health care waste management including waste from immunization activities exists.
� All 514 (100%) districts have updated micro-plans that include activities to raise immunization coverage.
� District coverage survey in 31 districts and 10 provinces was conducted in 2015.
� 83% spending on routine vaccine financed by the government.
� 76% spending on routine immunization programme financed by the central government.
� Out of 514 districts, 328 (64%) districts had > 80% coverage for DTP-Hib-HepB3, 217 (42%) districts had > 90% coverage for MCV1.
Source: WHO/UNICEF joint reporting form (JRF) 2015
Disclaimer: The boundaries and names shown and the designations used on all the maps do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries.
Table 1: Basic information1 2015Division/Province/State/Region 34
District 416
City 98
Village 79,411
Population density (per sq. km) 132
Population living in urban areas 52%
Population using improved drinking-water sources
85%
Population using improved sanitation 59%
Total expenditure on health as % of GDP 3.0%
Births attended by skilled health personnel 83%
Neonates protected at birth against NT 85%
Total population 255 461 686
Live births (LB) 4 893 435
Children <1 year 4 794 791
Children <5 years 24 065 506
Children <15 years 69 857 406
Pregnant women 5 382 779
Women of child bearing age (15-49 years)
51 981 127
Neonatal mortality rate 14.4 (per 1000 LB)
Infant mortality rate 24.5 (per 1000 LB)
Under-five mortality rate 29.3 (per 1000 LB)
Maternal mortality ratio 190 (per 100 000 LB)
1 SEAR annual EPI reporting form, 2015 and WHO, World Health Statistics 2015
Vaccine Age of administration
HepB 0 to 7 days of birth
BCG 1 month
OPV 1 month, 2 months, 3 months, 4 months
DTP-Hib-HepB 2 months, 3 months, 4 months, 18 months
Measles 9 months, 24 months
DT 6 -7 years
Td 7-8 years, 8-9 years
TT Females 15 to 39 years
Vitamin A 6 – 59 months
EPI history � EPI launched in 1977.
� HepB vaccine introduced in 1997.
� AD syringe introduced in 2002.
� MCV2 introduced in 2004.
� DTP-HepB vaccine introduced in 2004 (in phases)
� IPV introduced in one province in 2007.
� Hib Pentavalent (DTP-Hib-HepB) vaccine introduced in four provinces in 2013 and gradually expended to all provinces by 2014.
� Type 2 component of OPV withdrawn on 04 April 2016 by switching from tOPV to bOPV.
� IPV vaccine launched in national routine immunization programme from July 2016.
Table 2: Immunization schedule, 2015
Source: cMYP 2015-2019 and EPI/MOHSource: WHO/UNICEF joint reporting form (JRF) 2015
Figure 10: Immunity against measles: Immunity profile by age in 2015*
Figure 12: Confirmed (Lab and Epi linked) measles outbreak associated cases, by age, 2010-2015
Table 8: Suspected sporadic and Outbreak associated measles and rubella cases, 2010-2015
Table 9: Quality of field and laboratory surveillance for measles and rubella, 2012-2015
Table 10: Performance of Laboratory Surveillance, 2012-2015
Figure 14: Laboratory network
Figure 11: Immunity against measles: Immunity profile by age in 2016*
Figure 13: Unimmunized confirmed (Lab and Epi linked)measles outbreak associated cases, by age, 2010-2015
* Modeled using MSP tool ver 2 assuming the schedule and measles containing vaccine (MCV) coverage remain unchanged and Measles SIAs in 180 high risk districts in 2016.
* Modeled using MSP tool ver 2 based on coverage data up to 2015
Source: SEAR annual EPI reporting form
Source: Monthly VPD Reporting to WHO/SEARO * Laboratory confirmed & epidemiologically- linked
Source: SEAR Annual EPI Reporting Form, 2015 ND=No data
Source: SEAR Annual EPI Reporting Form, 2015 ND=No data
Source: SEAR annual EPI reporting form
Year
Routine/sporadic cases Outbreak associated cases
No. of suspected
case No. of death
No. of lab-confirmed
measles cases
No. of lab-confirmed
rubella cases
No. of suspected
outbreak
No. of Outbreak
Investigated No. of caseNo. of death
No. of measles
outbreak*
No. of confirmed
measles case*
No. of confirmed
rubella outbreak*
No. of confirmed
rubella cases*
2010 19 111 6 659 750 188 132 3 044 7 90 2 066 40 504
2011 23 282 0 1 175 1 808 356 286 4 993 14 251 3 747 60 586
2012 18 798 4 429 1 565 163 144 2 328 4 65 1 117 76 939
2013 11 521 1 689 707 128 96 1 677 1 71 803 24 310
2014 12 943 7 1471 713 173 119 2 104 21 114 1 285 7 69
2015 8 185 1 818 826 68 34 831 0 19 227 7 108
Year
No. o
f Sus
pect
ed M
easl
es
Case classification (number) Indicators
Measles Rubella
Disc
arde
d n
on-m
easl
es
non-
rube
lla c
ases
Annu
al in
cide
nce
of
confi
rmed
Mea
sles
cas
es
per m
illio
n to
tal p
opul
atio
n
Annu
al in
cide
nce
of
confi
rmed
Rub
ella
cas
es p
er
mill
ion
tota
l pop
ulat
ion
Prop
ortio
n of
all
susp
ecte
d m
easl
es a
nd ru
bella
cas
es
that
hav
e ha
d an
ade
quat
e in
vest
igat
ion
initi
ated
with
in
48 h
ours
of n
otifi
catio
n
Disc
arde
d no
n-m
easl
es
non-
rube
lla in
cide
nce
per
100
000
tota
l pop
ulat
ion
Prop
ortio
n of
sub
natio
nal
adm
inis
trativ
e un
its
repo
rting
at l
east
two
disc
arde
d no
n-m
easl
es n
on-
rube
lla c
ases
per
100
000
to
tal p
opul
atio
n
Prop
ortio
n of
sub
-nat
iona
l su
rvei
llanc
e un
its re
porti
ng
to th
e na
tiona
l lev
el o
n tim
e
Lab-
confi
rmed
Epi-L
inke
d
Clin
ical
ly-c
onfir
med
Lab-
confi
rmed
Epi-L
inke
dTarget - - 80% 2 80% 80%
2012 18 798 429 ND ND 1 565 ND 1 561 1.75 6.18 ND 0.61 ND 64.23
2013 11 521 747 ND ND 742 ND 1 376 3.01 2.93 ND 0.54 ND 60.22
2014 12 943 2 241 ND ND 906 ND 2 606 8.85 3.58 ND 1.03 ND 22.06
2015 8 185 818 ND ND 826 ND 1 434 3.23 3.26 ND 0.57 ND 37.76
Year
% Serum specimen collected from
suspected measles cases
Total Serum Specimen
received in Laboratory
% serum specimens
tested
Specimen Positive for
Measles IgM
Specimen Positive for Rubella IgM
% Results within 4 of
receipt
% Outbreak tested
for viral detection
Genotypes detected
No. % No. % Measles Rubella
2012 25 4 657 89 403 10% 921 25% 68 ND ND ND
2013 45 5 169 100 996 20% 1 042 25% 97 ND ND ND
2014 65 8 448 99 5 194 62% 1 140 36% 60 2 ND ND
2015 142 11 608 99 2 511 22% 4 239 47% 40 ND ND ND
For contact or feedback:
Expanded Program on Immunization
Ministry of Health, Jakarta, Indonesia
Tel : +62 21 4257044, Fax: +62 21 4257044
Email: [email protected] or [email protected]
www.depkes.go.id
Immunization and Vaccine Development (IVD)WHO-SEARO, IP Estate, MG Marg, New Delhi 110002, India
Tel: +91 11 23370804, Fax: +91 11 23370251
Email: [email protected], www.searo.who.int/entity/immunization
0%10%20%30%40%50%60%70%80%90%
100%
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19
Perce
nt of
popu
lation
Age (in years)Susceptible Immune due to past infectionProtected by SIAs Protected by routine vaccination with 2nd doseProtected by routine vaccination with 1st dose Protected by maternal antibodies
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19
Perce
nt of
popu
lation
Age (in years)Protected by maternal antibodies Protected by routine vaccination with 1st doseProtected by routine vaccination with 2nd dose Protected by SIAsImmune due to past infection Susceptible
0100200300400500600700800900
2010 2011 2012 2013 2014 2015
<1 year 1-4 years 5-9 years 10-14 years 15+ years
n=1627 n=2617 n=1119 n=365 n=1553 n=227
050
100150200250300350400450500
2010 2011 2012 2013 2014 2015
<1 year 1-4 years 5-9 years 10-14 years 15+ years
n=1107(68%)
n=1468(56%)
n=775(69%)
n=280(77%)
ND ND
Polio, measles & rubella laboratoriesNational Institute of Health Research and Development (NIHRD), JakartaBiofarma, BandungPublic Health Laboratory, Surabaya
Japanese encephalitis laboratory NIHRD, JakartaPublic Health Laboratory, Denpasar
Measles & rubella laboratoryPublic Health Laboratory, YogyakartaPublic Health Laboratory, PalembangPublic Health Laboratory, MakassarPublic Health Laboratory, Jakarta
E P I F a c t S h E E t
World Health Organization• SEARO/FGL/IVD • 31 August 2016 Immunization andVaccine Development
South-East Asia Region
World Health Organization• SEARO/FGL/IVD • 31 August 2016 Immunization andVaccine Development
South-East Asia Region